帕罗西汀联合坦度螺酮治疗52例难治性抑郁症的效果分析
|
摘要
目的探讨应用帕罗西汀联合坦度螺酮对难治性抑郁症的治疗效果。方法选取本院于2016年2月～2018年2月收治的难治性抑郁症的患者共52例,随机分为观察组和对照组。对照组患者单独应用帕罗西汀,观察组患者则应用帕罗西汀联合坦度螺酮的治疗。比较两组患者的临床疗效,治疗起效的时间,HAMD量表评分及并发症发生率。结果观察组治疗的有效率为92.31%,显著高于对照组(73.08%),差异有统计学意义(P<0.05);观察组患者治疗平均起效时间为(5.35±1.02)d,显著短于对照组,差异有统计学意义(P <0.05);观察组中,出现1例情绪低落,1例食欲不佳,对照组则出现2例情绪低落和1例恶心,两组患者并发症发生率比较,差异无统计学意义(P> 0.05);观察组和对照组治疗后HAMD各因子得分比较,观察组均显著低于对照组,总分的对比,观察组亦显著低于对照组,差异有统计学意义(P <0.05)。结论帕罗西汀联合坦度螺酮对难治性抑郁症患者的治疗效果良好,起效快,且无显著不良反应,临床应用前景光明。
Objective To explore the curative effects of paroxetine combined with tandospirone in treatment of 52 patients with refractory depression. Methods 52 patients with refractory depression who were admitted and treated in our hospital from February 2016 to February 2018 were selected and they were andomly divided into observation group and control group. Patients in the control group were treated with paroxetine alonewhile patients in the observation group were treated with paroxetine combined with tandospirone. The clinical curative effects, onset time, HAMD score, incidence of complications were observed and compared between the two groups. Results The effective rate of treatment in the observation group was92.31%, which was significantly higher than that of the control group(73.08%).The difference was statistically significant(P<0.05).The mean onset time of treatment in the observation group was(5.35±1.02) days, which was significantly shorter than that in the control group. The difference was statistically significant(P < 0.05). In the observation group, there were 1 case of depression and1 case of poor appetite. But in the control group there were 2 cases of depression and 1 case of nausea. There was no significant difference in the incidence of complications between the two groups(P > 0.05). By comparing factors of HAMD, the score of each factor of HAMD in the observation group was significantly lower than that in the control group. The total score of the observation group was also significantly lower than that of the control group. The above differences were statistically significant(P < 0.05).Conclusion Paroxetine combined with tandospirone in treatment of patients with refractory depression has good curative effect,short onset time and no significant adverse reactions, which has bright prospects of clinical application.
Objective To explore the curative effects of paroxetine combined with tandospirone in treatment of 52 patients with refractory depression. Methods 52 patients with refractory depression who were admitted and treated in our hospital from February 2016 to February 2018 were selected and they were andomly divided into observation group and control group. Patients in the control group were treated with paroxetine alonewhile patients in the observation group were treated with paroxetine combined with tandospirone. The clinical curative effects, onset time, HAMD score, incidence of complications were observed and compared between the two groups. Results The effective rate of treatment in the observation group was92.31%, which was significantly higher than that of the control group(73.08%).The difference was statistically significant(P<0.05).The mean onset time of treatment in the observation group was(5.35±1.02) days, which was significantly shorter than that in the control group. The difference was statistically significant(P < 0.05). In the observation group, there were 1 case of depression and1 case of poor appetite. But in the control group there were 2 cases of depression and 1 case of nausea. There was no significant difference in the incidence of complications between the two groups(P > 0.05). By comparing factors of HAMD, the score of each factor of HAMD in the observation group was significantly lower than that in the control group. The total score of the observation group was also significantly lower than that of the control group. The above differences were statistically significant(P < 0.05).Conclusion Paroxetine combined with tandospirone in treatment of patients with refractory depression has good curative effect,short onset time and no significant adverse reactions, which has bright prospects of clinical application.
引文
[1]全东明,黄世伟,郭光全,等.300例抑郁症患者的中医体质辨识分析[J].中国医药指南,2014,12(22):279-280.
[2]张继红,王化宁,闫庆红,等.几种新型抗抑郁药治疗抑郁症首次发病患者的疗效比较[J].临床精神医学杂志,2012,22(3):145-147.
[3]付华斌,陈峰.难治性抑郁症的研究进展[J].解放军医药杂志,2011,23(3):31-32.
[4]毋炳奎.坦度螺酮联用帕罗西汀治疗难治性抑郁症的疗效观察[J].中国医药指南,2013,11(11):465.
[5]侯广伟.帕罗西汀联合坦度螺酮治疗抑郁伴焦虑的临床观察[J].临床合理用药,2017,10(7A):72-73.
[6]金小苏,许学明,许德河,等.艾司西酞普兰与帕罗西汀治疗单项抑郁症的临床疗效及安全性研究[J].中国临床药理学杂志,2015,31(10):812-814.
[7]马永春,陈正昕,金卫东.奥卡西平联合选择性5-羟色胺再摄取抑制剂治疗激越性抑郁的开放性研究[J].中华神经医学杂志,2010,9(7):744-746.
[8]朱羞阳,佟洋,李驰荣.选择性5-羟色胺再摄取抑制剂与奥氮平联合治疗难治性抑郁症的临床疗效[J].东南国防医药,2013,15(2):125-127.
[9]郑娅丽,赵志才,陈红,等.帕罗西汀对绝经后焦虑抑郁患者雌激素水平和认知功能的影响[J].国际精神病学杂志,2015,42(4):69-72.
[10]殷冬梅,阮祥燕.妇科手术对卵巢功能及女性生活质量影响的研究进展[J].中国医药导报,2013,10(18):164-166.
[11]李淑娟,付凤伟,刘金林.盐酸多奈哌齐联合帕罗西汀对血管性痴呆合并抑郁患者认知功能和神经功能的影响[J].中国当代医药,2013,20(9):73-74.
[12]高金松,宋学勤,庞礼娟.坦度螺酮联合SSRIs类药物治疗抑郁症疗效和安全性的研究[J].中国神经精神疾病杂志,2012,38(5):279,283,288.
[13]陈元林.坦度螺酮联用帕罗西汀治疗难治性抑郁症的临床研究[J].中外医疗, 2011,30(14):125.
[14]Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke[J].Arch Gen Psychiatry,2010, 67(2):187-196.
[15]王真真,张有志,宫泽辉,等.抑郁症治疗的新靶点和新策略[J].中国药理学与毒理学杂志,20l0,24(5):364-368.
[16]陈剑峰,张美胡,袁伟明.氟西汀合并小剂量利培酮治疗难治性抑郁症的效果及安全性评估[J].中国当代医药,2017,24(25):122-124.
[2]张继红,王化宁,闫庆红,等.几种新型抗抑郁药治疗抑郁症首次发病患者的疗效比较[J].临床精神医学杂志,2012,22(3):145-147.
[3]付华斌,陈峰.难治性抑郁症的研究进展[J].解放军医药杂志,2011,23(3):31-32.
[4]毋炳奎.坦度螺酮联用帕罗西汀治疗难治性抑郁症的疗效观察[J].中国医药指南,2013,11(11):465.
[5]侯广伟.帕罗西汀联合坦度螺酮治疗抑郁伴焦虑的临床观察[J].临床合理用药,2017,10(7A):72-73.
[6]金小苏,许学明,许德河,等.艾司西酞普兰与帕罗西汀治疗单项抑郁症的临床疗效及安全性研究[J].中国临床药理学杂志,2015,31(10):812-814.
[7]马永春,陈正昕,金卫东.奥卡西平联合选择性5-羟色胺再摄取抑制剂治疗激越性抑郁的开放性研究[J].中华神经医学杂志,2010,9(7):744-746.
[8]朱羞阳,佟洋,李驰荣.选择性5-羟色胺再摄取抑制剂与奥氮平联合治疗难治性抑郁症的临床疗效[J].东南国防医药,2013,15(2):125-127.
[9]郑娅丽,赵志才,陈红,等.帕罗西汀对绝经后焦虑抑郁患者雌激素水平和认知功能的影响[J].国际精神病学杂志,2015,42(4):69-72.
[10]殷冬梅,阮祥燕.妇科手术对卵巢功能及女性生活质量影响的研究进展[J].中国医药导报,2013,10(18):164-166.
[11]李淑娟,付凤伟,刘金林.盐酸多奈哌齐联合帕罗西汀对血管性痴呆合并抑郁患者认知功能和神经功能的影响[J].中国当代医药,2013,20(9):73-74.
[12]高金松,宋学勤,庞礼娟.坦度螺酮联合SSRIs类药物治疗抑郁症疗效和安全性的研究[J].中国神经精神疾病杂志,2012,38(5):279,283,288.
[13]陈元林.坦度螺酮联用帕罗西汀治疗难治性抑郁症的临床研究[J].中外医疗, 2011,30(14):125.
[14]Jorge RE, Acion L, Moser D, et al. Escitalopram and enhancement of cognitive recovery following stroke[J].Arch Gen Psychiatry,2010, 67(2):187-196.
[15]王真真,张有志,宫泽辉,等.抑郁症治疗的新靶点和新策略[J].中国药理学与毒理学杂志,20l0,24(5):364-368.
[16]陈剑峰,张美胡,袁伟明.氟西汀合并小剂量利培酮治疗难治性抑郁症的效果及安全性评估[J].中国当代医药,2017,24(25):122-124.